Page 4 - Sofinnova Partners News Today

M&L Healthcare is a family-owned investment fund founded by shipping tycoon Michael Kum and his wife Lynda. Read more at straitstimes.com.

LimFlow will receive $250 million in cash and be eligible to receive up to $165 million in additional payments.

Sofinnova Partners, acting on behalf of the Sofinnova Crossover I SLP fund, has declared to the AMF that on November 21 it exceeded the thresholds of 20% of the capital and voting rights in GenSight...

LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce that they have entered into a license agreement under whic...

SIOUX FALLS, S.D., Nov. 20, 2023 -- SAB Biotherapeutics , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte...

SIOUX FALLS, S.D., Nov. 20, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing a fully-human anti-thymocyte

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel...

15.11.2023 - Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system ...

Redx Pharma will admit £14m new shares to AIM tomorrow as selective DDR1 inhibitor, RXC009, shows positive early signs.